Brokers Issue Forecasts for ACAD Q1 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of ACADIA Pharmaceuticals in a report issued on Thursday, February 27th. HC Wainwright analyst A. Fein forecasts that the biopharmaceutical company will earn $0.10 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ Q2 2025 earnings at $0.16 EPS, Q3 2025 earnings at $0.20 EPS, Q4 2025 earnings at $0.24 EPS and FY2029 earnings at $2.32 EPS.

ACAD has been the subject of several other reports. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday. Deutsche Bank Aktiengesellschaft began coverage on ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday. StockNews.com cut ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Finally, Guggenheim cut ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $23.00 to $20.00 in a research note on Friday, January 3rd. Eight equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $24.00.

ACADIA Pharmaceuticals Price Performance

Shares of ACAD stock opened at $19.34 on Friday. The stock has a 50-day moving average of $18.37 and a 200-day moving average of $16.81. ACADIA Pharmaceuticals has a one year low of $14.15 and a one year high of $25.20. The stock has a market cap of $3.22 billion, a PE ratio of 24.79 and a beta of 0.37.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ACAD. Point72 Asset Management L.P. bought a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter valued at approximately $40,935,000. SG Americas Securities LLC increased its holdings in shares of ACADIA Pharmaceuticals by 380.3% during the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock valued at $45,576,000 after acquiring an additional 1,966,607 shares in the last quarter. Norges Bank bought a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter valued at approximately $25,555,000. Renaissance Technologies LLC increased its holdings in shares of ACADIA Pharmaceuticals by 204.2% during the fourth quarter. Renaissance Technologies LLC now owns 1,226,533 shares of the biopharmaceutical company’s stock valued at $22,507,000 after acquiring an additional 823,333 shares in the last quarter. Finally, Two Sigma Advisers LP increased its holdings in shares of ACADIA Pharmaceuticals by 160.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,263,200 shares of the biopharmaceutical company’s stock valued at $23,180,000 after acquiring an additional 778,900 shares in the last quarter. Institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.